Myelodysplastic Syndrome (MDS) Drugs Industry Valued at $5.12 Billion by 2029 With CAGR of 8.2% | Size and Share Insights
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#What Is the Forecast for the Myelodysplastic Syndrome (MDS) Drugs Market from 2024 to 2025?#_x000D_
The market for drugs treating myelodysplastic syndrome (MDS) has seen robust growth in recent years. Its size is projected to expand from $3.47 billion in 2024 to $3.73 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.5%. The considerable growth during historical periods can be credited to an aging population, progress in targeted treatments, clinical studies, and heightened awareness._x000D_
_x000D_
#What Is the Projected Market Size of the Myelodysplastic Syndrome (MDS) Drugs Market?#_x000D_
In the forthcoming years, the market size of drugs for myelodysplastic syndrome (MDS) is likely to witness considerable expansion. It is predicted to reach a value of $5.12 billion by 2029, growing at an annual compound rate (CAGR) of 8.2%. This projected growth can be associated with factors such as genomic research, immunotherapies, healthcare expansion worldwide, and biomarker discovery. Notable tendencies for the forecasted period involve personalized medicine, combination therapies, symptom management, as well as data sharing and cooperation._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=13043&type=smp_x000D_
_x000D_
#Who are the Major Competitors in the Myelodysplastic Syndrome (MDS) Drugs Market Outlook?#_x000D_
Major companies operating in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc._x000D_
_x000D_
#What Is Fueling Growth in the Myelodysplastic Syndrome (MDS) Drugs Market?#_x000D_
The growth of the myelodysplastic syndrome (MDS) drug market is anticipated to be driven by the increased prevalence of cancer treatments, such as chemotherapy and radiation. These types of treatments, which use medication to eliminate cancer cells and employ high radiation doses to eradicate cancer cells and diminish tumours, have the potential to harm the bone marrow’s stem cells. These cells are responsible for the production of new blood cells and their impairment interrupts the natural equilibrium of cell production, leading to the development of MDS. Medications for myelodysplastic syndrome (MDS) have been found to be beneficial in managing and treating the disorder, which is associated with irregular blood cell production in the bone marrow. Upon analysis by the European Society of Radiation Oncology (ESTRO), the anticipated cancer distribution in 2025 will lead to a 16% increase in radiotherapy treatment courses. This growth in cancer treatments, including chemotherapy and radiation, is therefore projected to be a driving force for the MDS drugs market. The myelodysplastic syndrome (MDS) drug treatment market is projected to be further boosted by the rising incidences of myeloid leukemia. Myeloid leukemia, a cancer type that originates in the bone marrow and affects the cell production of various types of blood cells, is seen as a growing major concern. MDS drugs target the root cause of leukemia to lessen the chances of complications, such as low blood cell counts, and reduce the need for intensive treatments such as chemotherapy and transplants while simultaneously improving survival rates. As per the data from the American Cancer Society, by January 2023, approximately 20,380 cases and 11,310 deaths resulting from acute myeloid leukemia (AML) are expected amongst adults. Therefore, the increasing prevalence of myeloid leukemia is a contributor to the expansion of the myelodysplastic syndrome (MDS) drug market._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=13043&type=smp_x000D_
_x000D_
#Which Myelodysplastic Syndrome (MDS) Drugs Market Segments Are Growing the Fastest?#_x000D_
The myelodysplastic syndrome (MDS) drugs market covered in this report is segmented –_x000D_
_x000D_
1) By Drug Type: Chemotherapy, Immunomodulatory Drugs_x000D_
2) By Route Of Administration: Oral, Parenteral_x000D_
3) By Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts_x000D_
4) By End User: Hospitals, Clinics, Ambulatory Surgical Centers_x000D_
_x000D_
Subsegments:_x000D_
1) By Chemotherapy: Hypomethylating Agents, Cytotoxic Agents_x000D_
2) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide_x000D_
_x000D_
#Which Industry Trends Are Shaping the Future of the Myelodysplastic Syndrome (MDS) Drugs Market?#_x000D_
Leading organizations in the myelodysplastic syndrome (MDS) drugs market are honing their focus on creating novel products, specifically targeted therapy, which aims to enhance patient outcomes, cater to unique customer requirements, and be compatible with the ecosystem. Targeted therapy in relation to myelodysplastic syndromes uses drugs designed expressly to target genetic abnormalities or molecular irregularities in cancer cells, promising improved results with its specific focus on abnormal cells, while limiting harm to healthy ones. For example, Tibsovo (ivosidenib) was approved by the U.S. Food and Drug Administration (FDA) in October 2023, for treating adults suffering from relapsed or refractory (R/R) myelodysplastic syndromes with an isocitrate dehydrogenase-1 (IDH1) mutation. To assess the effectiveness for this new usage, Tibsovo underwent testing in an open-label, single-arm, multicenter research including 18 adult patients who have relapsed or refractory MDS with an IDH1 mutation._x000D_
_x000D_
#Access The Full Report Here:#_x000D_
_x000D_
#Which Countries Are Leading the Myelodysplastic Syndrome (MDS) Drugs Market?#_x000D_
North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2024. The regions covered in myelodysplastic syndrome (MDS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa._x000D_
_x000D_
#Purchase The Full Report Today:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13043_x000D_
_x000D_
#This Report Delivers Insight On: #_x000D_
1. How big is the myelodysplastic syndrome (mds) drugs market, and how is it changing globally?_x000D_
2. Who are the major companies in the myelodysplastic syndrome (mds) drugs market, and how are they performing?_x000D_
3. What are the key opportunities and risks in the myelodysplastic syndrome (mds) drugs market right now?_x000D_
4. Which products or customer segments are growing the most in the myelodysplastic syndrome (mds) drugs market?_x000D_
5. What factors are helping or slowing down the growth of the myelodysplastic syndrome (mds) drugs market?_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 2071930708_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
